טוען...
Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle
Mavacamten (MYK-461) is a small-molecule allosteric inhibitor of sarcomeric myosins being used in preclinical/clinical trials for hypertrophic cardiomyopathy treatment. A better understanding of its impact on force generation in intact or skinned striated muscle preparations, especially for human ca...
שמור ב:
| הוצא לאור ב: | J Gen Physiol |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Rockefeller University Press
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8077167/ https://ncbi.nlm.nih.gov/pubmed/33891673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1085/jgp.202012789 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|